Calithera Biosciences Inc. (CALA) 12.93 $CALA Calithera

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:06 PM

Calithera Biosciences Inc. (CALA) 12.93 $CALA

Calithera Biosciences Announces Clinical Data Presentation at ASCO 2015
GlobeNewswire - Wed Apr 22, 8:00AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, will be presented at the 51 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois. Clinical results to be presented include updated data from Calithera's Phase I trial in solid tumors. Calithera will hold an investor and analyst briefing Saturday, May 30, 2015 in Chicago, Illinois at 6:30 p.m. CT.
CALA: 12.93 (-1.06)

Calithera Biosciences Highlights Results From Six Preclinical Abstracts at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Tue Apr 21, 6:45AM CDT
-Potential Biomarker Response to CB-839 Among KRAS and EGFR Mutant Cell Lines
CALA: 12.93 (-1.06)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT

SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.06 (+0.45), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)

BUYINS.NET: CALA SqueezeTrigger Price is $18.90. There is $860,475 That Short Sellers Still Need To Cover.
M2 - Wed Apr 15, 2:56AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Catalina Lighting Inc (NASDAQ:CALA) in real time and just received an alert that CALA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 44700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $18.90. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CALA: 12.93 (-1.06)

Calithera Biosciences to Present at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 8:05AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 14 Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Wednesday, April 15, 2015 at 3:40 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.
CALA: 12.93 (-1.06)

3 Stocks Breaking Out on Unusual Volume
at The Street - Fri Mar 27, 12:56PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
SWKS: 96.83 (+1.41), AXLL: 42.83 (-0.58), CALA: 12.93 (-1.06)

Calithera Biosciences (CALA) Crumbles: Stock Falls by 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 7:55AM CDT
Calithera Biosciences saw a big move last session, as the company’s shares fell by 7%. This reverses the recent trend for CALA as the stock is now up around 22%
LCI: 66.45 (-0.28), CALA: 12.93 (-1.06)

Calithera Biosciences reports FQ4 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:22PM CDT

CALA: 12.93 (-1.06)

Calithera Biosciences Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 26, 3:05PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal fourth quarter and year ended December 31, 2014. As of December 31, 2014, cash and cash equivalents totaled $102.0 million.
CALA: 12.93 (-1.06)

Pre-Earnings Calithera Biosciences Inc. Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Mar 26, 6:00AM CDT
Calithera Biosciences Inc. (NASDAQ: CALA) based in San Francisco, CA a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer will be reporting fourth quarter and year-end earnings this morning. Anticipation of this release has driven the recent investor interest in the shares of Calithera. Rollercoaster - like activity was observed for the past 4 trading days.
CALA: 12.93 (-1.06)

Calithera Biosciences (CALA) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise roughly 19% on the day.
LCI: 66.45 (-0.28), CALA: 12.93 (-1.06)

Calithera Biosciences to Report Fourth Quarter and Year-End 2014 Financial Results on Thursday, March 26, 2015
GlobeNewswire - Fri Mar 20, 7:30AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Thursday, March 26, 2015. Company management will host a conference call on Thursday, March 26, 2015 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
CALA: 12.93 (-1.06)

Calithera Biosciences Announces Five Data Presentations at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Wed Mar 18, 3:30PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the upcoming presentation of five preclinical abstracts, highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. Details for the two oral presentations and three poster presentations are as follows:
CALA: 12.93 (-1.06)

Calithera Biosciences (CALA) Jumps: Stock Moves Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise over 10% on the day.
LCI: 66.45 (-0.28), CALA: 12.93 (-1.06)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:15AM CST

NGL: 27.75 (+0.29), FNSR: 21.29 (-0.16), SSH: 4.18 (+0.04), YY: 61.86 (+1.12), CNAT: 6.31 (-0.15), ASTI: 1.07 (+0.04), CLDN: 13.59 (-2.77), AXN: 1.77 (+0.01), VMEM: 3.73 (-0.02), BLRX: 2.12 (unch), GENE: 4.88 (-0.05), OREX: 7.39 (+0.22), SKUL: 11.25 (+0.30), CALA: 12.93 (-1.06), AVEO: 2.04 (+0.12), MSO: 5.93 (-0.09), GALE: 1.39 (unch), CKP: 11.03 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Melrose Fire Station Reaches Steel Topping Milestone

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

DKS Facing Class Action Over Stock Slump Allegations

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

AI Memory Growth Pushes Limits at GMIF2026 Summit

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Salveo Home Care Faces Class Action Over Labor Violations

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...